Targets › CCR8
5 programs from 5 companies in 7 trials: 4 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Apr 2027.
G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18. Regulates monocyte and eosinophil chemotaxis. (UniProt, P51685)
Open in Phaseline: the race on CCR8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| LaNova Medicines | LM-108 Anti-CCR8 monoclonal antibody | CCR8 | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Advanced Solid Tumor | Aug 2028 |
| Bristol-Myers Squibb | Imzokitug Anti-CCR8 monoclonal antibody | CCR8 | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Pancreatic Adenocarcinoma | Sep 2028 |
| Bayer | BAY3375968 (Lanerkitug) Anti-CCR8 antibody | CCR8 | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| Domain Therapeutics Australia | DT-7012 anti-CCR8 monoclonal antibody | CCR8 | Phase 1 | Advanced Solid Tumors | Sep 2027 |
| Takeda | TAK-188 CCR8 antagonist targeting regulatory T cells (Tregs) | CCR8 | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2028 |
Advanced Solid Tumors (2) Advanced or Metastatic Solid Tumors (1) Locally Advanced or Metastatic GC and GCJ Adenocarcinoma (1) Advanced Solid Tumor (1) Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (1) Metastatic Pancreatic Adenocarcinoma (1)
small molecule (2), mixed (2), antibody (1)
Takeda (1) LaNova Medicines (1) Domain Therapeutics Australia (1) Bristol-Myers Squibb (1) Bayer (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.